A cyclooxygenase-2-inhibitor containing as an active ingredient a compound having cyclooxygenase-2-inhibitory activity and exhibiting low toxicity that causes only minor side effects. The active compound is represented by the following formula (1) or (1'): ##STR1## wherein R.sup.1 represents a hydrogen atom or a C1-C3 alkyl group; R.sup.2 represents a hydrogen atom, a hydroxyl group, an organic group capable of being bound through its thiol group within the molecule, or R.sup.1 and R.sup.2 may j...

The invention relates to the isolation of novel cyclooxygenase type 1 (COX-1) variant enzymes. More specifically, the invention relates to the identification of cyclooxygenase transcripts harboring inton 1, or fragment thereof, of cyclooxygenase 1. The invention further relates to the diagnosis of aberrant cyclooxygenase type 1 variant gene or gene product; the identification, production, and use of compounds which modulate cyclooxygenase type 1 variant gene expression or the activity of the cyc...

This invention provides a compound of the following formula: ##STR1## or the pharmaceutically acceptable salts thereof, wherein Ar is heteroaryl; X.sup.1 and X.sup.2 are independently selected from halo, C.sub.1 -C.sub.4 alkyl, hydroxy, C.sub.1 -C.sub.4 alkoxy, amino, C.sub.1 -C.sub.4 alkanoyl, carboxy, carbamoyl, cyano, nitro, mercapto, (C.sub.1 -C.sub.4 alkyl)thio, (C.sub.1 -C.sub.4 alkyl)sulfinyl, (C.sub.1 -C.sub.4 alkyl)sulfonyl, aminosulfonyl, or the like; R.sup.1 is selected from hydrogen,...

Selective inhibitors of cyclooxygenase-2 are used to treat liver disease and in combination with anti-viral drugs to treat virus-caused liver disorders. Selective inhibitors of cyclooxygenase-2 which also inhibit the synthesis of cyclooxygenase-2 improve over the efficacy of conventional selective inhibitors of cyclooxygenase-2 in the treatment of inflammatory conditions, Alzheimer's disease and cancer.

The present invention relates to cyclooxygenase-2 (COX-2) selective inhibitors of formula I: ##STR1## pharmaceutical compositions containing them, to their medicinal use, and to their preparations. The compounds of the invention are particularly useful in the treatment or alleviation of inflammation and inflammation associated disorders, such as, for example, rheumatoid arthritis and osteoarthritis, and in the relief of pain, such as, for example, pain associated with surgery or trauma, in mamma...

Compounds having the structure ##STR1## or a pharmaceutically acceptable salt thereof have activity as inhibitors of cylooxygenase and 5-lipoxygenase, reduce the biosynthesis of leukotrienes B.sub.4, C.sub.4, D.sub.4, and E.sub.4 and cylooxygenase products such as prostaglandins and thromboxane and are useful in the treatment of inflammatory and allergic disease states. The compounds have the structure indicated above wherein A is selected from (a) optinally substituted carbocyclic aryl, (b) opt...

A class of substituted isoxazolyl compounds is described for use in treating cyclooxygenase-2 related disorders. Compounds of particular interest are defined by Formula I ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3, are described in the specification.

The invention relates to a method of detecting concentrations of cyclooxygenase-2 in a mammal, the method comprising: administering to the mammal a diagnostically effective amount of a cyclooxygenase-2 selective agent, which is capable of being detected in vivo; and b) detecting the agent so the concentration of cyclooxygenase-2 is detected.

Disclosed is a method for selectively inhibiting cyclooxygenase-2 in an animal having a cyclooxygenase-2 activity by delivering into the animal an amount of a conjugated linoleic acid effective to reduce cyclooxygenase-2 activity in the animal.

The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.